- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00046319
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Patients With Moderate to Severe Pulmonary Arterial Hypertension
Study Overview
Detailed Description
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sidney, Australia
- St. Vincent's Hospital
-
-
-
-
-
Brussels, Belgium
- Erasmus University
-
-
-
-
Cedex
-
Clamart, Cedex, France, 92141
- Hôpital Antoine Béclère
-
-
-
-
-
Giessen, Germany, 35392
- University of Gießen
-
Hannover, Germany, 30625
- Hannover Medical School
-
-
-
-
-
Bologna, Italy, 40136
- University of Bologna - Institute of Cardiology
-
-
-
-
California
-
Los Angeles, California, United States, 90089
- University of Southern California
-
San Diego, California, United States, 92037
- University of California San Diego Medical Center
-
San Francisco, California, United States, 94143
- University of California - San Francisco
-
Stanford, California, United States, 94305
- Stanford University
-
Torrance, California, United States, 90502
- Los Angeles County Harbor-UCLA Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80262
- University of Colorado Health Sciences Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush Presbyterian
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- New York Presbyterian Hospital
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Heart Care Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
--Disease Characteristics--
- Current diagnosis of either PPH or PAH secondary to the scleroderma spectrum of disease (e.g., mixed connective tissue disease, systemic lupus erythematosus, systemic sclerosis, or overlap syndrome), anorexigen use, or human immunodeficiency virus (HIV) infection at the time of screening
By means of a right heart catheterization, completed prior to Screening Visit subjects must meet all of the following hemodynamic criteria:
- Mean pulmonary arterial pressure of >/= 25 mmHg
- Pulmonary vascular resistance >3 mmHg/L/min
- Pulmonary capillary wedge pressure or left ventricle end diastolic pressure of <15 mmHg
- Stable on conventional therapy for PAH, including diuretics, digoxin, or supplemental oxygen, for at least one month prior to the Screening Visit
Subjects with a diagnosis of HIV must have stable disease status at the time of screening. The subject may be enrolled if they meet the definition of a stable HIV status defined as:
- No addition of medications for treatment of HIV in the last two months
- No active opportunistic infection at the time of screening
- No hospitalizations due to HIV within the past four weeks
- Able to walk at least 150 meters, but no more than 450 meters, in a six minute walk test at the time of the Screening Visit
- No pulmonary arterial hypertension due to or associated with congenital heart disease, interstitial lung disease, chronic obstructive pulmonary disease, or chronic thrombotic and/or embolic disease, as documented by a historical echocardiogram, chest X-ray, ventilation/perfusion (V/Q) scan, and/or pulmonary arteriogram
No subjects who have, as measured by a historical pulmonary function test:
- Total lung capacity (TLC) <70% of predicted normal or;
- Forced expiratory volume in one second (FEV1) <65% of predicted normal
--Other Criteria--
Subjects are excluded if they have:
- A serum ALT or AST lab value that is greater than 1.5 times the upper limit of normal at any time during the Screening Period
- Contraindication to treatment with an endothelin receptor antagonist
- Demonstrated noncompliance with previous medical regimens
- A recent history of abusing alcohol or illicit drugs
- Participated in a clinical study involving another investigational drug or device within four weeks before the Screening Visit or at any time during the study
--Patient Characteristics--
Women of childbearing potential must:
- Have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Randomization Visit. Women who are surgically sterile or those who are post-menopausal for at least two years are not considered to be of childbearing potential
- Agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit
- All males must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the Informed Consent Form
Excluded:
- Pregnant or breastfeeding
- Have a history of malignancies within the past five years, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix
- Any other disease which, in the investigators opinion, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject
--Prior/Concurrent Therapy--
- Stable on conventional therapy for PAH, including diuretics, digoxin, or supplemental oxygen, for at least one month prior to the Screening Visit
Excluded Therapies:
- IV inotropes within two weeks prior to the Screening Visit
- Chronic prostanoid therapy (epoprostenol, treprostinil, iloprost, beraprost, or any other investigational prostacyclin derivative) within four weeks prior to the Screening Visit
- Bosentan within four weeks prior to the Screening Visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Change from baseline to Week 12 in six minute walk distance
|
Secondary Outcome Measures
Outcome Measure |
---|
Borg Dyspnea Index
|
WHO Functional Classification
|
Change from baseline to Week 12 in:
|
Subject Global Assessment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lewis Rubin, MD, UCSD Medical Center
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMB-220
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
Mads ErsbøllRecruitingPulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionDenmark
Clinical Trials on BSF 208075
-
Gilead SciencesCompletedPulmonary Hypertension
-
The Hong Kong Polytechnic UniversityPrince of Wales Hospital, Shatin, Hong Kong; Innovation and Technology Commission...RecruitingFoot Drop | Cerebrovascular Stroke | Foot Inversion DeformityChina
-
Medical University of South CarolinaCompletedChild Abuse | Substance Abuse | Child NeglectUnited States
-
University of AarhusAarhus University Hospital; Zimmer BiometWithdrawn
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
City of Hope Medical CenterActive, not recruitingHIV Infection | AIDS-related Non-Hodgkin Lymphoma | AIDS-related Plasmablastic Lymphoma | AIDS-related Primary Effusion LymphomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHematopoietic/Lymphoid Cancer | Graft Versus Host DiseaseUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditionsUnited States